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Abstract
Toxoplasma gondii can be responsible for congenital toxoplasmosis leading to mild or severe sequelae, and for life-threatening infections
in immunocompromised hosts. A new 5¢-nuclease real-time PCR assay that targets the 300-fold repeated AF146527 DNA sequence
(TaqMan-AF-PCR) has been developed and its performance for diagnosis of toxoplasmosis and treatment follow-up has been assessed.
A retrospective analysis was first performed with 144 clinical specimens previously analysed for the presence of T. gondii DNA by a
PCR–ELISA assay that targets the B1 gene of T. gondii (B1-PCR–ELISA). Fifteen samples, all from patients with clinically proven toxo-
plasmosis, were negative according to B1-PCR–ELISA and positive according to TaqMan-AF-PCR. A prospective analysis was then per-
formed with 203 consecutive clinical specimens received at the laboratory of Parasitology of Saint-Louis Hospital during a 4-month
period. The diagnosis of toxoplasmosis in two patients was made according to the TaqMan-AF-PCR whereas the B1-PCR–ELISA failed
to make diagnosis. Additionally, iterative samples from a patient with cerebral and disseminated toxoplasmosis, already tested using a
B1 real-time PCR assay, were tested using the TaqMan-AF-PCR and a Light Cycler real-time PCR assay targeting the same repetitive
AF146527 sequence (LC-AF-PCR). Detection was achieved with the TaqMan-AF-PCR, with a mean gain of 7.1 and 3.3 amplification
cycles when compared with the B1 real-time PCR and the LC-AF-PCR, respectively. This study demonstrates the higher sensitivity of
the 5¢-nuclease real-time PCR assay developed for the AF146527 DNA sequence and confirms the interest of using this highly repeated
target to improve the diagnosis of toxoplasmosis.
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Introduction
Toxoplasma gondii is a protozoan that infects a wide range of
mammalian hosts. Human infection is frequent, but often
remains asymptomatic in immunocompetent individuals.
However, T. gondii can be responsible for fetal infections
leading to mild or severe sequelae, and for life-threatening
infections in immunocompromised hosts. HIV-infected
patients with low CD4 counts and allogeneic haematopoietic
stem cell transplant (SCT) recipients are particularly
vulnerable to severe toxoplasmosis, mainly as a result of
reactivation of a previously acquired latent infection [1–5]. In
these particularly susceptible hosts, early diagnosis is essen-
tial in order to initiate therapy with sulfadiazine and pyri-
methamine. Several PCR assays have been developed, mainly
for the T. gondii B1 and 18S rRNA genes, using conventional
PCR [6–11] or real-time quantitative PCR [12–16]. In recent
years, a genomic 300-fold repetitive 529-bp DNA sequence
has been identified and used for diagnostic conventional PCR
and real-time PCR using fluorescence resonance energy
transfer (FRET) hybridization probes [17–20]. As hybridiza-
tion probes cannot be used in all real-time PCR systems, we
have designed a new 5¢-nuclease real-time PCR assay with a
TaqMan probe targeting the previously described repetitive
529-bp AF146527 DNA sequence and have assessed its per-
formance for diagnostic purposes and treatment follow-up.
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Materials and Methods
Toxoplasma gondii DNA
Tachyzoites of the T. gondii RH strain were obtained from
ascitic fluids, sampled at day 3, from Swiss mice infected
intraperitoneally. The tachyzoites were counted in a Malassez
haemocytometer. DNA was extracted using a QIAamp DNA
Mini kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions.
Patients and clinical specimens
A retrospective analysis was performed on 144 clinical
specimens that had been sent to the laboratory for diag-
nosis of toxoplasmosis, treatment follow-up of toxoplasmo-
sis, or routine surveillance of immunocompromised
patients. The samples had been previously analysed for the
presence of T. gondii DNA by a PCR–ELISA assay that tar-
gets the B1 gene of T. gondii [11]. Clinical specimens origi-
nated from 47 patients without clinical or radiological
evidence of toxoplasmosis and from 21 patients with clini-
cal or radiological symptoms of toxoplasmosis (cerebral in
five patients, ocular in two, both cerebral and ocular in
three, disseminated in eight, congenital in three). Among
these samples, 42 blood samples had been collected
sequentially from a single patient presenting with cerebral
and disseminated toxoplasmosis; these samples had also
been previously tested by a real-time PCR assay targeting
the B1 gene [21], providing an opportunity to compare
the performances of different PCR assays targeting differ-
ent genes for the diagnosis and treatment follow-up of
toxoplasmosis.
A prospective analysis was then performed on 203 con-
secutive clinical specimens received at the laboratory of Par-
asitology of Saint-Louis Hospital from 1 September to 31
December 2004 for PCR diagnosis of toxoplasmosis. These
203 serial samples originated from 61 patients, six of whom
had a clinical history of toxoplasmosis. Each clinical specimen
was tested both by the PCR–ELISA assay that targets the
B1 gene of T. gondii [11] and by the new TaqMan-based real-
time PCR assay.
Blood buffy coats were obtained from 7 mL of blood
drawn in EDTA by using Histopaque 1119 (Sigma Aldrich,
Saint Quentin Fallavier, France). DNA extraction was then
performed on the leucocyte layer by using a QIAamp DNA
Mini kit (Qiagen) according to the manufacturer’s instruc-
tions. Similarly, DNA extraction was performed on biopsies,
placenta, or 200 lL of whole blood drawn in EDTA, serum,
cerebrospinal fluid, bronchoalveolar lavage fluid, or aqueous
humour using a QIAamp DNA Mini kit.
PCR assays
All PCR assays used in the study were ‘laboratory-developed’
PCR assays. A PCR–ELISA (B1-PCR–ELISA) amplifying a
130-bp fragment of the T. gondii B1 gene was carried out as
previously described [21], using the primers described by
Robert-Gangneux et al. [11].
The TaqMan-based real-time PCR assay (TaqMan-AF-PCR)
developed for this study amplifies an 83-bp fragment of a
529-bp unit repetitive DNA sequence in the T. gondii genome,
described by Homan et al. [17] (Genbank accession numbers
AF146527 and AF487550), hereafter called the AF146527
DNA sequence. The primers TG-F (5¢-CTTCGTCCA
AGCCTCCGA-3¢) and TG-R (5¢-GACGCTTTCCTCGTG
GTGAT-3¢), and the TaqMan probe 5¢-CCCTCGCCCTCTT
CTCCACTCTTCAA-3¢ were designed using Primer Express
Software (Applied Biosystems, Foster City, CA, USA). The
TaqMan probe was labelled at the 5¢ end with 6-carboxyfluo-
rescein and at the 3¢ end with 6-carboxytetramethylrhod-
amine. Real-time quantitative PCR was performed on an
Applied Biosystems 7500 PCR system, in a final volume of
25 lL using the TaqMan Universal Master Mix with uracyl-
DNA-glycosylase (Applied Biosystems). After optimization,
primers were used at 0.4 lM and the probe was used at
0.2 lM. After 2 min at 50C and 10 min at 95C, amplifica-
tion consisted of 45 cycles of 15 s of denaturation at 95C,
followed by 1 min of annealing and extension at 60C. For
quantification, six serial ten-fold dilutions of T. gondii DNA
(RH strain) were included in each amplification run and PCR
results (Ct values) were converted into numbers of tachy-
zoites per millilitre by interpolation from the parasite dilution
curve. In order to search for the presence of PCR inhibitors,
each sample was also tested in the reaction mixture
described above, supplemented with TaqMan Exogenous
Internal Positive Control Reagents (Applied Biosystems) at
the concentrations recommended by the manufacturer.
When the Ct value of the Internal Positive Control was
increased by more than three in the presence of the clinical
sample, the sample was ten-fold diluted and retested.
The specificity of the TaqMan-AF-PCR assay was assessed
by testing DNA extracted from the following purified or
concentrated parasites and fungi: Cryptosporidium parvum,
C. hominis, C. meleagridis, C. felis, C. canis, Isospora belli, Leish-
mania infantum, L. donovani, L. major, L. tropica, Giardia duode-
nalis, Entamoeba coli, E. dispar, E. hartmanni, Endolimax nana,
Pseudolimax butschlii, Enterocytozoon bieneusi, Encephalitozoon
intestinalis, Encephalitozoon cuniculi, Encephalitozoon hellem,
Pneumocystis jirovecii, and Aspergillus fumigatus.
A Light-Cycler real-time PCR assay (LC-AF-PCR) targeting
the 529-bp AF146527 DNA sequence was performed on a
LightCycler 2.0 instrument using reagents from the
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LightCycler FastStart Master Hybridization Probes kit (Roche
Applied Science, Meylan, France) according to a previously
described protocol [18].
Statistical analysis
Repeated measures analysis of variance followed by Bonfer-
roni’s multiple comparison test were used to compare the
threshold cycles (Ct) of amplification obtained with the two
real-time PCR assays targeting the AF146527 DNA sequence
and the real-time PCR assay targeting the B1 gene. Statistical
analysis was performed using GraphPad Prism version 4.00
for Windows (GraphPad Software, San Diego, CA, USA).
Results
The sensitivity and linearity of the TaqMan-AF-PCR were
assessed by serial dilutions of T. gondii DNA (RH strain), to
achieve DNA concentrations ranging from 3 to 3 · 106 tachy-
zoites/mL of sample. The detection limit was 3 tachyzoite-
equivalents/mL of sample. The regression curve of Ct values
vs. the decimal logarithm of the equivalent number of tachy-
zoites per PCR reaction presented a coefficient of correla-
tion (r2) of 0.997 and a slope of )3.46. In order to test
whether there were significant differences in the quantifica-
tion performed on various strains of T. gondii, we used one
strain representative of the three major types of T. gondii
(RH as type I strain, RMS-1995-ABE as type II strain and
NED as type III strain), kindly provided by I. Villena and
D. Aubert (Centre de Ressources Biologiques Toxoplasma,
Faculte´ de Me´decine de Reims, France). For each strain, six
different solutions of tachyzoites were microscopically
counted and adjusted to an amount of 1000 tachyzoites per
PCR reaction, and tested by real-time PCR. One-way analysis
of variance showed that the number of tachyzoites assessed
by the TaqMan-AF-PCR was not significantly different among
the three strains (p 0.09). No amplification was observed
with DNA extracted from 22 other protists or fungi.
Among the 144 clinical specimens that were retrospec-
tively analysed, 72 were negative and 72 were positive
according to B1-PCR–ELISA. All 72 samples positive accord-
ing to B1-PCR–ELISA were positive according to TaqMan-
AF-PCR, whereas 15 (20.8%) of the 72 samples that were
negative according to B1-PCR–ELISA were positive according
to TaqMan-AF-PCR. All of these 15 positive samples origi-
nated from three allogeneic SCT recipients with dissemi-
nated toxoplasmosis and presenting with other Toxoplasma
PCR-positive samples according to both techniques. For two
patients, the TaqMan-AF-PCR was positive 4 and 10 days
earlier than the B1-PCR–ELISA.
Iterative blood and serum specimens sampled from an
unrelated cord blood SCT recipient with cerebral and dis-
seminated toxoplasmosis, whose case has been previously
reported [20], provided the opportunity to follow the evolu-
tion of parasite load under treatment according to TaqMan-
AF-PCR. Fig. 1 shows the slow decrease in parasite load
after the initiation of treatment with pyrimethamine and sul-
fadiazine on day 43 post transplantation. PCR on blood buffy
coats yielded the highest parasite load, with a peak of
29 000 tachyzoite-equivalents/mL on day 43 post transplanta-
tion (Fig. 1a). In whole blood, parasite loads were lower,
with a peak value of 4300 tachyzoite-equivalents (Fig. 1b),
and in sera, parasite loads were much lower, with a peak
value of only 15 tachyzoite-equivalents/mL (Fig. 1c).
The threshold cycles obtained using TaqMan-AF-PCR on
these samples were compared with those obtained previously
with a real-time PCR assay targeting the B1 gene [21] and
those obtained using the LC-AF-PCR [18]. The TaqMan-
AF-PCR allowed detection with lower Ct values: the mean
gain was 7.1 ± 2.4 amplification cycles when compared with
the real-time PCR assay on B1 gene (p <0.001) and 3.3 ± 3.2
amplification cycles when compared with the LC-AF-PCR
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FIG. 1. Evolution of parasite loads under treatment in iterative blood buffy coat (a), whole blood (b) and serum (c) specimens sampled from a
cord blood stem cell transplant recipient with cerebral and disseminated toxoplasmosis. The number of tachyzoites per millilitre of sample
assessed by the TaqMan-based real-time PCR assay that targets AF146527 DNA sequence is represented as a function of days post transplanta-
tion. Treatment with pyrimethamine plus sulfadiazine was started on day 43 post transplantation.
CMI Menotti et al. TaqMan real-time PCR assay for Toxoplasma gondii 365
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 363–368
(p <0.001). On blood buffy coats, T. gondii DNA was detect-
able 20 days longer with both the TaqMan-AF and LC-AF
PCR assays than with the assay targeting the B1 gene (Fig. 2a).
In whole blood, the presence of T. gondii DNA was detected
7 days earlier by both the TaqMan-AF and LC-AF PCR assays
than with the assay targeting the B1 gene (Fig. 2b). In sera,
T. gondii DNA was detected in 12 samples by the TaqMan-AF-
PCR, whereas only four samples were positive according to
the assay targeting the B1 gene and seven samples were
positive according to the LC-AF-PCR (Fig. 2c).
Among the 203 clinical specimens that were prospectively
examined for the presence of T. gondii DNA, nine were posi-
tive according to both the B1-PCR–ELISA and the TaqMan-
AF-PCR assays (Table 1). These samples originated from four
HIV-infected patients receiving no antiretroviral therapy:
three patients (P1–P3) presented neurological signs and typi-
cal brain lesions on computed tomography (CT) scans and
magnetic resonance imaging; one patient (P4) had pulmonary
and disseminated toxoplasmosis. Two specimens were
positive only according to TaqMan-AF-PCR, with low para-
site burdens: one was a serum collected from an HIV-
infected patient with clinically and radiologically confirmed
toxoplasmosis (P5), and the other one was a placenta,
obtained at delivery following a history of toxoplasmic sero-
conversion during pregnancy, with confirmed congenital
toxoplasmosis (P6) (proven child infection with intracranial
calcifications).
Discussion
The TaqMan-AF-PCR assay described here allowed toxoplas-
mosis diagnosis with improved sensitivity when compared
with both the PCR–ELISA assay and the real-time PCR assay
that target the B1 gene. These results are in agreement with
those of four studies: three studies comparing two FRET
hybridization probe real-time PCR assays targeting AF146527
and B1 genomic sequences [18–20] and one study comparing
two Sybr Green real-time PCR assays targeting both geno-
mic sequences [22].
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FIG. 2. Comparison of the Ct values obtained by the TaqMan-based real-time PCR assay that targets AF146527 DNA sequence, the Light-
Cycler real-time PCR assay that targets AF146527 DNA sequence and the Light-Cycler real-time PCR assay that targets B1 gene for the iterative
blood buffy coat (a), whole blood (b) and serum (c) specimens sampled from the patient whose evolution of parasite loads is represented in
Fig. 1. Specimens represented with a Ct value of 45 are specimens for which no amplification was detected after 45 cycles of amplification.
TABLE 1. Results of prospective assessment of the PCR–ELISA assay that targets the B1 gene and the TaqMan-based real-
time PCR assay that targets the AF146527 DNA sequence
Patient Clinical background Specimen Date PCR–ELISA
Real-time PCR
(no. tachyzoites/mL)
P1 HIV infection CSF 11 October + 3600
P2 HIV infection CSF 15 October + 71
P3 HIV infection CSF 22 November + 67
P4 HIV infection Whole blood 4 December + 7.9
Whole blood 6 December + 180
BAL fluid 11 December + 6200
Whole blood 13 December + 3900
Blood buffy coat 13 December + 360
Bone marrow 13 December + 16 000
P5 HIV infection Serum 21 December ) 3.3
P6 Toxoplasmic seroconversion
during pregnancy
Placenta 23 December ) 140
P7–P61 Variousa Variousb Various Negative Undetectable
+, presence of T. gondii DNA detected by PCR–ELISA; ), PCR–ELISA negative.
aAllogeneic stem cell transplantation, HIV infection, renal transplantation, pulmonary transplantation, idiopathic lymphopenia, toxoplasmic seroconversion during pregnancy.
bWhole blood, blood buffy coat, serum, cerebrospinal fluid (CSF), brain biopsy, bronchoalveolar lavage (BAL) fluid, aqueous humour, placenta.
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The improved sensitivity of these assays is related to the
high number of repeats of AF146527 DNA sequence in the
T. gondii genome [17,18,20], when compared with the 35-fold
repetitive B1 gene, even if the sensitivity also depends on the
optimization of the PCR assays. Additionally, the gain in
threshold cycles of amplification obtained with the TaqMan-
AF-PCR, compared with the LC-AF-PCR that targets the
same repeated genomic sequence, can be of interest, espe-
cially when working on samples with low parasite burdens,
such as the serum samples presented in Fig. 2c.
The specificity of our assay is assessed both by the
absence of cross reaction with DNA from the 22 other par-
asites and fungi tested and by the absence of false-positive
reactions in all tested samples from patients without toxo-
plasmosis (47 patients in the retrospective study and 55
patients in the prospective study).
In the prospective study, the increased sensitivity of the
TaqMan-AF-PCR assay allowed diagnosis of toxoplasmosis in
two cases that were not detected by the PCR–ELISA assay
that targets the B1 gene. The sequential follow-up of one
patient previously studied using the B1 real-time PCR [21]
also confirmed the higher sensitivity of detection of both
real-time PCR assays targeting the AF146527 DNA
sequence. Using the TaqMan-AF-PCR assay, T. gondii DNA
could be detected in whole blood until day 102 post trans-
plantation (vs. until day 91 with the B1 PCR), i.e. after
2 months’ treatment. This is, to our knowledge, the first
observation of such a prolonged parasitaemia despite well-
conducted and compliant treatment with pyrimethamine and
sulfadiazine.
The prolonged presence of T. gondii DNA in this patient’s
blood could be related to the disseminated form of the dis-
ease, with a high peak of parasitaemia (29 000 tachyzoites/
mL of blood buffy coat), and to the profound immunosup-
pression linked to cord blood stem cell transplantation. In
other parasitic diseases, such as visceral leishmaniasis, it has
been assumed that the persistence of parasite DNA in blood
after treatment does not necessarily confirm the presence of
viable circulating parasites [23,24]. In the absence of argu-
ment supporting this hypothesis concerning toxoplasmosis
(especially in immunocompromised patients), we consider
that the persistent detection of T. gondii DNA in blood justi-
fies the maintenance of anti-T. gondii treatments and close
follow-up by PCR.
The TaqMan-AF-PCR also appeared to be suitable for
early diagnosis of toxoplasmosis in immunocompromised
patients, especially in HIV-infected patients and SCT recipi-
ents. A recent study showed an incidence of Toxoplasma
infections of 16% among haematopoietic SCT recipients with
previously positive Toxoplasma serology [25]. Several reports
have highlighted the unusual presentation of cerebral toxo-
plasmosis in these patients, with the absence of typical CT
scan ring-enhanced lesions [21,26,27], or frequent pulmonary
or disseminated infections without cerebral localization
[5,28,29]. In this context, a sensitive diagnostic tool such as
TaqMan-AF-PCR could be efficient for post-transplant
screening of patients at high risk for Toxoplasma reactivation,
i.e. those who are seropositive for T. gondii and recipients of
cord blood transplants. It could be performed on a weekly
basis for patients not receiving prophylaxis, and during
defined high-risk periods and in case of unexplained fever.
For early diagnosis, both whole blood and buffy coat samples
should be examined.
Altogether, these results demonstrate the high sensitivity
and specificity of the TaqMan-based PCR assay targeting the
AF146527 genomic sequence and confirm the interest of
using this highly repeated sequence [18] to improve the
molecular diagnosis and treatment follow-up of toxoplasmo-
sis.
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